HOPE-3 Under the Microscope: Data, Framing, and Regulatory Reality
Why "Statistically Positive Data", Procedural FDA Alignment, and Approval Risk Remain Fundamentally Misaligned
Forward from Alpha Talon
At Alpha Talon, we are deliberately pivoting greater emphasis toward our long portfolio coverage. This is intentional. We want our readers to become disciplined, fundamentals-first investors, and high-quality long ideas are structurally healthier, easier to underwrite, and more repeatable across market cycles, whether you are a n…
